Introduction
Lung cancer is one of the most common human malignant tumors and is the leading cause of cancer-related deaths in the world. 1 Based on global cancer statistics, ~1,824,700 new cases of lung cancer were clinically diagnosed, with an estimated 1,589,900 deaths in 2012. 1 Human lung cancer consists of two major types: small-cell lung cancer and non-small-cell lung cancer (NSCLC). NSCLC is the most common type and accounts for 85% of lung cancer cases, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and adenosquamous carcinoma. 2, 3 Due to the lack of an early diagnostic method, .40% of NSCLC patients have developed metastases submit your manuscript | www.dovepress.com
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Yang et al by the time of diagnosis, 4 and the average 5-year survival rate is currently 18%. 5 Therefore, early diagnosis is crucial for improving the survival rate. 6 Epigenetic modifications are involved in humor cancers, DNA methylation, as a crucial mechanism of epigenetic changes, leads to target gene silencing, and plays a key role in the carcinogenesis and progression of cancer. [7] [8] [9] A large number of studies have reported that genes with aberrant promoter methylation are significantly correlated with lung cancer. [10] [11] [12] [13] Located on the human chromosome 9p21, the INK4/ARF locus encodes three cell-cycle inhibitory proteins involving p15 INK4B , p14 ARF , and p16
INK4A
; p16 INK4A is encoded by cyclin-dependent kinase inhibitor 2A (CDKN2A), p14 ARF is encoded by an alternative reading frame of CDKN2A, and p15 INK4B is encoded by cyclin-dependent kinase inhibitor 2B (CDKN2B), which plays roles in the regulation of p53 and retinoblastoma pathways. [14] [15] [16] Inactivation of p15
INK4B
, p14 ARF , and p16
INK4A as tumor suppressor genes is one of the most common events in human cancers. [17] [18] [19] The loss of p15
expression via promoter methylation has been reported in lung cancer cell lines. 20 Seike et al reported that aberrant methylation of p15 INK4B was not detected in lung cancer tissues. 21 Wang et al reported that aberrant DNA methylation may be the most common mechanism of inactivating cancer-related genes in lung cancer, including p15 INK4B . 22 Yanagawa et al reported that aberrant promoter methylation of p14 ARF was correlated with lung cancer. 23 Zhang et al reported that p14 ARF promoter methylation was not correlated with lung cancer. 24 Thus, there were also contradictory results concerning the methylation frequency of p14 ARF and p15 INK4B promoter in lung cancer samples. The current study was first analyzed to better identify the association between p14 ARF and p15
promoter methylation and lung cancer.
Materials and methods search for eligible studies
A systematic search was performed through online literature databases (PubMed, EMBASE, EBSCO, Wangfang, and Cochrane Library). The following search strategy was used: "methylation," "hypermethylation," or "promoter methylation"; and "lung cancer," "lung carcinoma," or "lung tumor"; and "p14," "p14 ARF ," "p15," "p15 INK4B ," "CDKN2B," "cyclin-dependent kinase inhibitor 2." The search was updated till June 24, 2016. Additionally, we manually searched the references of the selected studies to obtain additional studies. The full texts of all of the qualified studies were published.
inclusion criteria
Studies were included if they met all the following criteria: 1) Study was an original case-control study on the association between p14 ARF or p15 INK4B gene promoter methylation and lung cancer; 2) Patients were diagnosed as lung cancer based on histopathological examination; 3) Study had sufficient data to calculate the pooled odds ratios (ORs) or hazard ratios (HRs) and 95% confidence intervals (CIs) for the meta-analysis; and 4) The most recent study with more information was selected when several publications contained duplicated data.
Data extraction
The data obtained from the publications included first author's name, year of publication, country, ethnicity, sample type, methylation detection method, histology, number of participants, overall survival (OS), and methylation frequency. The various sample types included tissue, bronchoalveolar lavage fluid (BALF), and blood samples, clinicopathological parameters, such as gender status, smoking status, tumor differentiation, and tumor stage. The selection of eligible studies and data extraction were independently performed by two reviewers (LY and WD).
statistical analysis
The current meta-analysis was performed using the STATA software (version 12.0, Stata Corporation, College Station, TX, USA). The pooled ORs and 95% CIs were calculated to determine the correlation between p14 ARF or p15 INK4B gene promoter methylation and lung cancer. The pooled HR with 95% CI was used to evaluate the impact of p14 ARF promoter methylation on OS of NSCLC patients. Between-study heterogeneity was estimated based on the Cochran's Q-test and I 2 statistic. 25 A random-effects model was applied for the meta-analysis with significant heterogeneity (I 2 .50% and P,0.1); otherwise, the fixed-effects model was used. 26, 27 P-value ,0.05 was considered to be significant.
Results
study characteristics
As shown in Figure 1 , 269 potentially relevant articles were obtained from the PubMed, EMBASE, EBSCO, Wangfang, and Cochrane Library databases. After a series of selection procedures, a total of 12 studies involving 625 lung cancer samples and 488 nontumor samples were included in the current study. Eight studies with 505 NSCLC samples and 419 nontumor samples analyzed the relationship between p14 ARF promoter methylation and NSCLC. (Figure 3 ), indicating that p15 INK4B promoter methylation was not significantly associated with a risk of lung cancer. 
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INK4A
, p14
ARF
, and p15
INK4B genes by DNA methylation of the C-phosphate-G (CpG) islands of the promoter regions has been reported to be involved in the carcinogenesis and be an early biologic event in many cancers. [37] [38] [39] [40] Based on a meta-analysis, Gu et al reported that p16
INK4A promoter methylation may play a key role in the tumorigenesis of lung cancer. 41 However, whether p14 ARF or p15 INK4B promoter methylation plays a crucial role in the carcinogenesis of lung cancer, which remains to be certified. The results were inconsistent with regard to p14 ARF and p15 INK4B promoter methylation rate in lung cancer. For example, Topaloglu et al reported that p14 ARF promoter was absent in methylation in NSCLC. 30 Fischer et al reported that p14 ARF promoter had a methylation frequency of 30.4% in NSCLC. 29 In addition, Seike et al showed that p15 INK4B promoter had no methylation, 21 while Chaussade et al showed that p15 INK4B promoter had a methylation rate of 100% in lung cancer. 35 Therefore, we performed a metaanalysis to evaluate the strength of p14 ARF and p15 INK4B promoter methylation on lung cancer risk.
There was no evidence of the heterogeneity in the current meta-analysis, presenting no obvious publication bias. Our findings demonstrated that p14 ARF promoter methylation status had a significantly higher OR in NSCLC than in nontumor samples, while significant correlation was not observed between p15 INK4B promoter methylation and lung cancer, suggesting that p14 ARF promoter methylation may play an important role in the initiation of NSCLC. However, the result of p15 INK4B promoter methylation should be prudent as only 120 lung cancer samples were included in our analysis.
Next, subgroup analyses of the ethnic population (Asians and Caucasians) and sample type (tissue, BALF, and blood) were conducted to find the different association between p14 ARF promoter methylation and different subgroups in NSCLC versus nontumor samples. Significant correlation between Asian population and Caucasian population in p14 ARF promoter methylation was found in subgroup analysis of ethnicity, which suggested that Asian and Caucasian populations were susceptible to p14 ARF promoter methylation. According to subgroup analysis of sample type, a significant association between p14 ARF promoter methylation and NSCLC was observed in tissue subgroup, but not in BALF and blood subgroups. The results should be carefully considered as only one or two studies with smaller subjects were analyzed in BALF and blood subgroups. : 73 patients with NSCLC), more studies with larger sample size should be done in the future.
Limitations
There were several limitations in the present meta-analysis. First, there might be selection bias because eligible studies were restricted to articles published in English and Chinese, studies with other language and other styles, such as conference abstracts were missed. Second, the main ethnic population consisted of Asian and Caucasian populations, and other ethnicities, such as Africans, were insufficient. Third, only smaller subjects were included in BALF and blood subgroups; more studies with larger sample sizes are essential to further determine whether p14 ARF promoter methylation can become a promising biomarker based on BALF or blood detection. Fourth, only 1 study reported that p14 ARF promoter methylation was not associated with the prognosis of NSCLC patients in OS; further large-scale studies with larger subjects are very necessary in the future. Finally, sample sizes on clinicopathological features were smaller in this study.
Conclusion
The results suggested that p14 ARF promoter methylation may play a pivotal role in the carcinogenesis of lung cancer, but not p15 INK4B promoter methylation. In addition, p14 ARF promoter methylation was a susceptible gene for Asians and Caucasians. Aberrant promoter methylation of p14 ARF and p15 INK4B was not associated with clinicopathological features. Additional studies with larger subjects are needed to further validate our results.
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